It is important to note that the use of tirofiban in the RESTORE study did not reach statistical significance levels as to the reduction of MACEs, probably because a sub-dose of the drug was used fig.1.
Es importante resaltar que el uso de tirofiban en el estudio RESTORE no alcanzó significancia estadística para reducción de ECM, probablemente por haber utilizado subdosis del fármaco Fig.
Com a evolução da terapia antiagregante plaquetária apareceram os tienopiridínicos.